Search Results

7 Hills Pharma Inc., a clinical-stage pharma company leveraging a novel mechanism of action to safely enhance the effectiveness of cancer immunotherapies, was awarded $4.7 million from the Cancer Prevention and Research Institute of Texas to support its cell/gene therapy development program.

7 Hills Pharma LLC announced that it has been awarded $13.5MM in nondilutive grant funds from the Cancer Prevention & Research Institute of Texas to advance 7HP349, its first-in-class oral selective integrin activator into a Phase 1b/2a clinical trial in patients who are resistant to PD-1-based therapies.

Zealand Pharma A/S announces the receipt on 9 January 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from Avoro Capital Advisors LLC.

FSD Pharma Inc. is pleased to announce that it has entered into an investor relations services agreement with IR Agency LLC effective May 22, 2024.

Future Pak LLC (“Future Pak”) today announced that it has submitted three proposals since February to acquire all of the outstanding shares of common stock of Vanda Pharmaceuticals, Inc. (“Vanda”) (NASDAQ: VNDA), and confirms that its most recent proposal to acquire Vanda for cash consideration of $7.25 to $7.75 per share remains open for Vanda and its Board of Directors to consider.

EA Pharma Co., Ltd. and Ensho Therapeutics, Inc. announced that the two companies have signed a worldwide exclusive license agreement for the rights to develop, manufacture and commercialize novel oral inflammatory bowel disease treatments EA1080 and a portfolio of other oral selective α4β7 integrin antagonists for the global market excluding Japan, China, Hong Kong, Macau, South Korea, Taiwan and ASEAN.

An appreciation for practicality, independent thinking and patient care can help disrupt the bureaucracy of Big Pharma.

Athira Pharma will cut about 49 positions, including two people in the C-suite. The announcement follows the company’s disappointing results for its investigational Alzheimer’s therapy.